TROP2-Targeting Antibody-Drug Conjugates
The expert panel discusses TROP2 as a target for patients with cancer who are receiving antibody-drug conjugates.
Source: onclive.com
Ascent Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Ascent Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Ascent Trial Today - Breaking & Trending Today
Newly Defined Breast Cancer Targets Expand TNBC Treatment Options
Kevin Kalinsky, MD, MS, discusses genetic sequencing in triple-negative breast cancer, the significance of breast cancer tumor board discussions for informing further research and optimizing patient care, and how future directions in breast cancer treatment are building off the current benefits of drugs classes like antibody-drug conjugates.
Source: onclive.com